The purpose of the study is to investigate the plasma levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) at the diagnosis and after treatment of sepsis, and to determine whether it has a diagnostic and prognostic value in late-onset neonatal sepsis.
Infection is a leading cause of neonatal morbidity and mortality worldwide. The clinical presentation of neonatal infection is subtle and nonspecific. Microbiologic cultures of clinical specimens, the gold standard for diagnosis, have low sensitivity and are not available in time to influence initial therapy. Therefore, reliable and rapid in vitro tests are needed for early diagnosis and management of infection in neonates. suPAR, secreted from the cells (neutrophils, lymphocytes, macrophages, endothelial cells) has recently been reported to be a potential biomarker for several infection diseases. The levels of suPAR have not been studied in newborn infants yet.
Study Type
OBSERVATIONAL
Enrollment
120
Ankara University Faculty of Medicine, Department of Pediatrics
Ankara, Turkey (Türkiye)
Levels of suPAR in late-onset neonatal sepsis
Levels of suPAR will be dosed with suspicion of late-onset sepsis diagnosis at day 0 and at the end of the treatment. The evolution and the best cut-off values will be calculated for the diagnosis. Indices of sensibility, specificity, positive predictive value and negative predictive value will be calculated.
Time frame: three weeks
Level of plasma C-reactive protein
Plasma C-reactive protein levels to confirm the diagnostic usefulness of suPAR measurements at diagnosis and end of the treatment
Time frame: three weeks
the white blood cell count
the white blood cell counts to confirm the diagnostic usefulness of suPAR measurements at diagnosis and end of the treatment
Time frame: three weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.